公开(公告)号：US20210054073A1

公开(公告)日：2021-02-25

申请号：US16984365

申请日：2020-08-04

申请人： Merck Patent GmbH

发明人： Horacio G. Nastri ,  Christel Iffland ,  Olivier Leger ,  Qi An ,  Mark Cartwright ,  Sean D. McKenna

IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K31/555 ,  A61K39/395 ,  A61K31/675 ,  A61K31/7068 ,  A61K39/00 ,  A61K31/282 ,  A61K31/513 ,  A61K31/519

摘要： The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.

公开(公告)号：US20210030764A1

公开(公告)日：2021-02-04

申请号：US16943323

申请日：2020-07-30

申请人： University of Louisiana at Lafayette

发明人： Radhey Srivastava

IPC分类号： A61K31/555

摘要： Disclosed herein is a method of treating patients with NSCLC subtypes of cancer by reducing tumor burden, comprising administering at least one dose of purified Ruthenium (III) Pyrazole complexes to patients suffering from NSCLC, wherein said dose is therapeutically sufficient. In one or more embodiments, the Ruthenium III Pyrazole is RuCl3(DMSO)(dmPyz)2.

公开(公告)号：US10881701B2

公开(公告)日：2021-01-05

申请号：US16427605

申请日：2019-05-31

申请人： Sarah Morgan ,  Karl Holtzer

发明人： Sarah Morgan ,  Karl Holtzer

IPC分类号： A01N43/00 ,  A01N43/46 ,  A61K31/55 ,  A61K36/28 ,  A61K31/355 ,  A61K31/375 ,  A61K31/122 ,  A61K31/07 ,  A61K31/593 ,  A61K31/714 ,  A61K31/4415 ,  A61K31/51 ,  A61K31/525 ,  A61K31/455 ,  A61K31/197 ,  A61K31/519 ,  A61K31/19 ,  A61K33/18 ,  A61K31/194 ,  A61K31/555 ,  A61K31/14 ,  A61K33/06 ,  A61K39/00

摘要： The present invention provides formulations and methods for formulation administration that support an individual's body during vaccination and adaptive immune response. The individuals who can benefit from these formulations and methods for formulation administration are infants, children and adults. The formulations comprise ingredients that may be administered prior to, concurrent with or subsequent to the vaccination. The formulations and methods for formulation administration of the present invention preferably act by selectively targeting enzymatic reactions, epigenetic expression, and an individual's various metabolic pathways in support of immune system homeostasis, maintaining balance between oxidative stress and methylation, fostering balance between Th1 and Th2 responses, or a combination thereof, during vaccination and adaptive immune responses to improve vaccine response and reduce vaccine side effects.

公开(公告)号：US10821128B2

公开(公告)日：2020-11-03

申请号：US16081045

申请日：2017-03-01

申请人： ONXEO ,  INSTITUT CURIE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

发明人： Marie Dutreix ,  Nathalie Berthault

IPC分类号： A61K31/713 ,  A61K45/06 ,  A61K31/704 ,  A61K33/24 ,  A61K31/513 ,  A61K31/555 ,  C12N15/113 ,  A61P35/04 ,  A61K9/00

摘要： The present invention relates to the use of a DBait molecules by systemic routes without any combination with an endosomolytic agent.

公开(公告)号：US10821095B2

公开(公告)日：2020-11-03

申请号：US16081554

申请日：2017-03-01

申请人： Bold Therapeutics, Inc.

发明人： Suzanne Bakewell ,  Jyothi Sethuraman

IPC分类号： A61K31/416 ,  A61K45/06 ,  A61K39/395 ,  C07K16/28 ,  A61K31/555 ,  A61P35/00 ,  A61K31/7068 ,  A61K39/00

摘要： IT-139, sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemotherapy and immuno-oncology agents to be more effective in treating cancer.

公开(公告)号：US20200330468A1

公开(公告)日：2020-10-22

申请号：US16866276

申请日：2020-05-04

申请人： Isofol Medical AB

发明人： Göran U. Carlsson ,  Bengt Gustavsson ,  Elisabeth Odin ,  Yvonne Wettergren ,  Anders Vedin

IPC分类号： A61K31/519 ,  A61K45/06 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/555 ,  A61P35/00 ,  A61K39/395 ,  C07K16/22 ,  A61K9/00 ,  A61K31/282 ,  A61K31/4545

摘要： The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF.

公开(公告)号：US10799594B2

公开(公告)日：2020-10-13

申请号：US16231166

申请日：2018-12-21

申请人： Massachusetts Institute of Technology

发明人： Jeremiah A. Johnson ,  Longyan Liao

IPC分类号： A61K47/60 ,  C07F15/00 ,  A61K31/4745 ,  A61K31/555 ,  A61K47/58 ,  A61K31/704 ,  A61P35/00

摘要： Described herein are platinum-based brush-arm star polymers (Pt-BASPs), or a pharmaceutical composition thereof, for delivery of platinum-based agents, such as cisplatin. Also provided are methods and kits involving the Pt-BASPs, or a pharmaceutical composition thereof, for treating proliferative diseases such as cancers (e.g., lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, breast cancer, pancreas cancer, liver cancer, kidney cancer, or prostate cancer) in a subject.

公开(公告)号：US10781227B2

公开(公告)日：2020-09-22

申请号：US16266509

申请日：2019-02-04

申请人： biolitec Unternehmensbeteiligungs II AG

发明人： Claudia S. Gutsche ,  Arno Wiehe ,  Benjamin F. Hohlfeld ,  Burkhard Gitter ,  Volker Albrecht

IPC分类号： C07F15/00 ,  C07F15/06 ,  C07F15/02 ,  C07F15/04 ,  C07F1/08 ,  C07F3/06 ,  C07F5/00 ,  C07F19/00 ,  A61K47/64 ,  A61K41/00 ,  A61P35/00 ,  A61P31/04 ,  A61P19/02 ,  C07F1/00 ,  A61K49/00 ,  C07F3/00 ,  A61K31/555

摘要： The present invention provides biologically active compounds and methods to obtain biologically active compounds that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of non-tumorous indications such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, ophthalmological or urological disorders. As the compounds exhibit also toxicity against targets (tumor cells, bacteria, inflammation-related cells) without light these biologically active compounds may also be used for the light-independent treatment of such indications. Preferred embodiments of the present invention consist of methods to synthesize metal or half-metal complex structures incorporating one or more substituted 2,3,5,6-tetrafluorophenyl-dipyrromethene (2,3,5,6-tetrafluorophenyldipyrrin) units. These dipyrromethenes (dipyrrins) can carry a variety of different substituents in the 4-position enabling a fine tuning of their biological or amphiphilic/hydrophilic properties. Another object of the present invention is to provide amphiphilic compounds with a higher membrane affinity and increased efficacy.

公开(公告)号：US10780141B2

公开(公告)日：2020-09-22

申请号：US15131743

申请日：2016-04-18

申请人： Sirbal Ltd.

发明人： Nadav Shraibom ,  Anu T. Singh ,  Manu Jaggi ,  Eran Steinberg

IPC分类号： A61K36/708 ,  A61K36/64 ,  A61K36/355 ,  A61K9/00 ,  A61Q5/02 ,  A61K47/22 ,  A61K8/49 ,  A61K8/36 ,  A61K47/12 ,  A61K8/37 ,  A61K47/14 ,  A61K8/42 ,  A61K47/18 ,  A61K8/44 ,  A61K8/362 ,  A61K8/368 ,  A61K8/34 ,  A61K47/10 ,  A61K8/892 ,  A61K47/34 ,  A61K8/46 ,  A61K47/20 ,  A61K8/19 ,  A61K47/02 ,  A61K47/36 ,  A61K8/73 ,  A61K47/44 ,  A61K8/92 ,  A61K8/58 ,  A61K47/24 ,  A61K36/185 ,  A61K36/815 ,  A61K31/555 ,  A61K36/65 ,  A61K31/4164 ,  A61K36/804 ,  A61K36/73 ,  A61K31/475 ,  A61K31/519

摘要： A shampoo, conditioner, cream, ointment or other topical treatment includes an active herbal combination of Sheng Di Huang, Da Huang and Jin Yin Hua for treating eczema, and/or another skin or scalp disorder.

公开(公告)号：US20200282002A1

公开(公告)日：2020-09-10

申请号：US16783481

申请日：2020-02-06

申请人： Medivir AB

发明人： Stephen M. Condon ,  Yijun Deng ,  Matthew G. Laporte ,  Susan R. Rippin

IPC分类号： A61K38/05 ,  C07D403/06 ,  C07K5/062 ,  A61K38/07 ,  A61K45/06 ,  C07D403/14 ,  C07K5/02 ,  A61K31/404 ,  A61N5/06 ,  A61N5/10 ,  C07K5/06 ,  C12N5/09 ,  A61K31/555

摘要： A SMAC mimetic and pharmaceutical compositions thereof and methods of use.